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Genetically susceptible C57BL/6 (B6) mice that are infected with the LP-BM5 isolate of murine retroviruses
develop profound splenomegaly, lymphadenopathy, hypergammaglobulinemia, terminal B-cell lymphomas,
and an immunodeficiency state bearing many similarities to the pathologies seen in AIDS. Because of these
similarities, this syndrome has been called murine AIDS (MAIDS). We have previously shown that CD154
(CD40 ligand)-CD40 molecular interactions are required both for the initiation and progression of MAIDS.
Thus, in vivo anti-CD154 monoclonal antibody (MAb) treatment inhibited MAIDS symptoms in LP-BM5-
infected wild-type mice when either a short course of anti-CD154 MAb treatment was started on the day of
infection or a course was initiated 3 to 4 weeks after LP-BM5 administration, after disease was established.
Here, we further characterize this required CD154-CD40 interaction by a series of adoptive transfer experi-
ments designed to elucidate which cellular subsets must express CD154 or CD40 for LP-BM5 to induce
MAIDS. Specifically with regard to CD154 expression, MAIDS-insusceptible B6 nude mice reconstituted with
highly purified CD41 T cells from wild-type, but not from CD154 knockout, B6 donors displayed clear MAIDS
after LP-BM5 infection. In contrast, nude B6 recipients that received CD81 T cells from wild-type B6 donors
did not develop MAIDS after LP-BM5 infection. B6 CD40 knockout mice, which are also relatively resistant to
LP-BM5-induced MAIDS, became susceptible to LP-BM5-induced disease after reconstitution with highly
purified wild-type B cells but not after receiving purified wild-type dendritic cells (DC) or a combined CD401
population composed of DC and macrophages obtained from B6 SCID mouse donors. Based on these and other
experiments, we thus conclude that the cellular basis for the requirement for CD154-CD40 interactions for
MAIDS induction and progression can be accounted for by CD154 expression on CD41 T cells and CD40
expression on B cells.
The LP-BM5 murine leukemia retrovirus (MuLV) isolate
causes an immunodeficiency syndrome in genetically suscepti-
ble mice such as the highly susceptible C57BL/6 (B6) strain.
This MuLV mixture includes ecotropic, recombinant mink cell
cytopathic focus-inducing, and replication-negative or -defec-
tive viruses, with the defective genome serving as the proximal
agent causing the syndrome (3, 7, 18, 22, 36). Many of the
described disease features of this LP-BM5-induced mouse im-
munodeficiency syndrome are similar to those seen in human
immunodeficiency virus (HIV)-infected individuals, hence the
designation murine AIDS (MAIDS). Noted disease similarities
are activation-related parameters such as hypergammaglobu-
linemia (hyper-Ig), splenomegaly, and lymphadenopathy; se-
verely dampened T- and B-cell responses; increased suscepti-
bility to infection, disease progression, and death upon exposure
to environmental pathogens that normally cause limited infec-
tions; and the development of terminal B-cell lymphomas (5, 6,
26, 27, 29, 34, 37, 40, 53).
It has been suggested that CD41 T cells and B cells are
required for LP-BM5 MAIDS induction (6, 53, 47). In these
experiments, in vivo depletion of CD41 T cells before LP-BM5
infection rendered genetically susceptible mice resistant to the
development of MAIDS (53). Similarly, after in vivo depletion
of B cells from birth in neonatal mice by the administration of
rabbit antibody to immunoglobulin M (IgM), followed by in-
fection with LP-BM5 virus, MAIDS failed to develop (6).
These studies, however, did not exclude the required involve-
ment of other cellular subsets in MAIDS pathogenesis and did
not experimentally address the possible interaction of these
subsets or the molecular basis for interaction.
We have recently examined the effect of CD154-CD40 in-
teractions in MAIDS initiation and progression (15, 16).
CD154 is transiently expressed on activated T cells, especially
murine CD41 T cells after stimulation through the T-cell re-
ceptor for antigen (2, 39), and once expressed serves as the
ligand for CD40, a 50-kDa membrane signaling protein re-
sponsible for driving B-cell activation and differentiation to
antibody secretion (51). In view of the fact that CD154-CD40
interactions had been shown to be important in a wide array of
immunological responses (1, 23, 44), we treated LP-BM5-in-
fected B6 mice in vivo with blocking anti-CD154 monoclonal
antibody (MAb), either during the first week of infection (15)
or chronically, starting at 3 to 4 weeks after LP-BM5 infection
(16). Both time courses of administered anti-CD154 MAb
were very effective in inhibiting MAIDS-associated splenomeg-
aly, hyper-Ig, and immunodeficiency. The data from these two
experimental approaches strongly suggested that CD154-CD40
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interactions are necessary for both the initiation and the pro-
gression of LP-BM5-induced MAIDS.
In the study presented here, we further characterize the
CD154-CD40 interaction in MAIDS by a series of in vivo
adoptive transfer experiments designed to elucidate which cel-
lular subsets in a susceptible B6 mouse must express CD154 or
CD40 for LP-BM5 virus-induced pathogenesis. Progression to
MAIDS was evaluated in reconstituted, LP-BM5-infected
nude CD154 knockout (k.o.) and CD40 k.o. mice, all on the B6
genetic background, by the following standard readouts of
MAIDS-associated symptoms, which we (15, 16) and others (3,
5, 6, 7, 18, 21, 36) have previously established: (i) spleen size,
with enlargement indicating MAIDS-associated B- and T-cell
lymphoproliferation; (ii) serum IgG2a levels, with increases
due to MAIDS polyclonal B-cell activation; (iii) splenic B-cell
responses to lipopolysaccharide (LPS) stimulation, with de-
creases indicative of B-cell-associated MAIDS-induced immu-
nodeficiency; and (iv) T-cell responses to either concanavalin
A (ConA) mitogen stimulation or allogeneic major histocom-
patibility complex stimulation (as determined by cytotoxic T-
lymphocyte [CTL] generation), with decreases indicative of
MAIDS-induced T-cell immunodeficiency.
MATERIALS AND METHODS
Mice. Seven-week-old male B6 mice were purchased from the National Insti-
tutes of Health (Bethesda, Md.), housed in the Dartmouth Medical School
Animal facility, and used when 8 to 10 weeks of age as control mice or spleen cell
donors. Breeding pairs of CD154 k.o. mice (fully backcrossed to B6) were
obtained from the Jackson Laboratory (Bar Harbor, Maine); the mice were
originally derived by Immunex Corporation (Seattle, Wash.) as previously de-
scribed (45). B6-backcrossed CD40 k.o. breeding pairs, derived as reported
elsewhere (24), for initial experiments were obtained from Anthony Hayward’s
laboratory (University of Colorado Health Science Center, Denver); mice for
later experiments were obtained from the Jackson Laboratory. Six-week-old B6
nude mice were purchased from the Jackson Laboratory. Equal numbers of nude
and k.o. mice, either three or four in a given experiment, were reconstituted with
various cell preparations (see below) before infection with LP-BM5 virus. B6
SCID mice, purchased from the Jackson Laboratory were used at 6 weeks of age
as spleen cell donors in a reconstitution experiment.
Cell lines. LB27.4, a murine B-cell hybridoma (H-2b,d), and P815, a murine
mastocytoma (H-2d), were cultured at 37°C with 5% CO2 in RPMI 1640 with 5%
fetal calf serum (FCS), L-glutamine, 2-mercaptoethanol and antibiotics (Gibco
BRL, Life Technologies, Grand Island, N.Y.).
LP-BM5 virus inoculations. LP-BM5 was prepared in our laboratory as pre-
viously described (26). G6 cells, cloned from SC-1 cells infected with the LP-BM5
virus mixture and originally provided by Janet Hartley and Herbert Morse, were
cocultured with uninfected SC-1 cells. Mice were infected intraperitoneally with
0.25 ml of a virus stock which was quantitated by an XC plaque assay (46) to
contain approximately 5 3 105 ecotropic PFU/ml and which postinoculation
caused MAIDS-related splenomegaly, as shown by at least a doubling of spleen
weight as early as 4 weeks after inoculation into B6 mice.
ELISA determinations of serum Ig. For measuring hyper-Ig, affinity-purified
goat anti-mouse IgG2a antibody (Southern Biotechnology Associates, Birming-
ham, Ala.), was diluted to 7 mg/ml in phosphate-buffered saline (PBS) to coat
96-well enzyme-linked immunosorbent assay (ELISA)-grade plates (Becton
Dickinson, Oxford, Calif.) overnight at room temperature. The plates were then
washed three times with PBS and blocked for 1 h with 5% bovine serum albu-
min–PBS (Sigma, St. Louis, Mo.) at 37°C. Sera obtained at the termination of all
LP-BM5 infection experiments were then plated and allowed to incubate for 2 h
at 37°C. The plates were washed three times with PBS, and alkaline phosphatase-
labeled goat anti-mouse Ig (Southern Biotechnology Associates) was added.
After a 2-h, 37°C incubation, p-nitrophenyl phosphate (Sigma) provided a col-
orimetric change which was then quantitated at 405 nm by an ELISA reader
(Dynatech Laboratories, South Hampton, United Kingdom).
Spleen cell responses to mitogens. Spleen cells (4 3 105) from control and
experimental mice were plated in triplicate into 96-well plates with medium
containing 5% FCS, L-glutamine, antibiotics, and a final concentration of 2 mg/ml
for ConA or 10 mg/ml for LPS. After 72 h, all wells were pulsed with 1 mCi of
[3H]thymidine (Dupont NEN, Boston, Mass.) and harvested (Packard, Meriden
Conn.) 6 h later for assessment of thymidine incorporation by scintillation count-
ing (Packard).
Generation of primary allogeneic CTL (allo-CTL) and 51Cr release assays.
Responder splenocytes (107) from experimental or control mice were mixed with
irradiated (8,000 rad) LB27.4 tumor cells at a responder-to-stimulator ratio of
35:1 in RPMI 1640 containing 5% FCS, antibiotics, and L-glutamine. These
cultures were maintained at 37°C in a 5% CO2 incubator for 6 days. P815 target
cells were resuspended in 100 ml of FCS and labeled with 100 ml of sodium
chromate (2 mCi/ml; Dupont NEN). After washing, 5 3 103 51Cr-labeled P815
target cells were plated in duplicate with various numbers of effector cells to
achieve effector-to-target ratios of 100:1, 20:1, and 4:1. The plates were centri-
fuged briefly and incubated at 37°C in 5% CO2 for 4 h. Aliquots of cell-free
supernatant (100 ml) were collected for counting on a gamma counter (Wallac,
LKB Gaithersburg, Md). Percent specific lysis was defined as [(a 2 b)/c] 3 100,
where a is experimental cpm released, b is spontaneous cpm released, and c is
freeze-thaw releasable (about 80% of total) cpm. The values for spontaneous
target cell release were 15% or lower, with the duplicate experimental percent
specific lysis values ranging 6 10% of the mean value.
Splenocyte subpopulation preparation. Splenocyte suspensions were labeled
with antibody-coupled paramagnetic beads (MACS; Miltenyi Biotec, Auburn,
Calif.) and subjected to column purification according to the manufacturer’s
protocol. The following purified cellular subsets were used in reconstitution
experiments.
(i) CD41 T-cell preparations. Spleen cell suspensions were incubated with
anti-CD8a beads, positively selecting for CD81 T cells. The flowthrough cellular
preparation was then labeled with anti-CD4 (L3T4) beads, and positive selection
yielded cell preparations which were $90% CD31 CD41, #7% B2201, and
#1% CD81 as detected by flow cytometric analysis.
(ii) CD81 T-cell preparations. Spleen cell suspensions were incubated with
anti-CD4 (L3T4) beads, and the flowthrough of this positive selection was then
incubated with anti-CD8a beads, with positive selection yielding cell prepara-
tions which were $89% CD8a1, #9% B2201, and #1% CD41.
(iii) B-cell preparations. Spleen cell suspensions were incubated with a cock-
tail of anti-CD43 (Ly48, leukosialin) and anti-CD11c magnetic beads. The
flowthrough of this positive selection was then positively selected with anti-CD19
magnetic beads and yielded cell preparations which were $98% CD191.
(iv) DC preparations. Spleen cell suspensions were obtained from B6 mice
which had received injections of 10 mg per day of purified Flt3 ligand subcuta-
neously for 9 days. These cell suspensions were incubated with mouse Ig as
specified by the manufacturer (Miltenyi Biotech) to block Fc receptor-mediated
magnetic labeling of macrophages and subsequently with anti-CDIIc paramag-
netic beads. After column purification, positively selected fractions were evalu-
ated by direct immunofluorescence for cell surface markers as described for DC
subsets in Flt3 ligand-treated mice (43) and were $71% CDIIc1 I-Ab1, $18%
CDIIc1 I-Ab2, and $68% CD401. Based on the reported number of DC present
in a collagenase-treated spleen from a non-Flt3-treated mouse (0.5% of the
viable lymphocytes) (8), we reconstituted each experimental CD40 k.o. mouse
with .10 DC splenic equivalents.
SCID spleen cell preparation. A cell suspension prepared from SCID spleens
contained no detectable CD4-, CD8-, or CD19-expressing cells and was 19%
CD401 CDIIc1 and 27% CD401 CD1lb1 by flow cytometric analysis.
All of the above cell preparations were injected intravenously via the tail vein,
and those recipient mice whose transfers we rated technically as suboptimal were
not used in these experiments.
PCR amplification. DNA was extracted from splenic tissues of reconstituted
and nonreconstituted CD40 k.o. mice and wild-type (w.t.) B6 mice as specified by
the manufacturer (Qiagen Inc., Valencia, Calif.). PCR amplification was per-
formed with primers specific for the CD40 gene product (CD40upG, 59-dGGC
AGTAAGACGATGTGACAACAGAG-39; CD40Holo, 59-dGAGATGAGAA
GGAAGAATGGGAAAAC-39) according to standard procedures. The
predicted 2,100-bp band was detected for all CD40 k.o. mice, and a 900-bp band
indicative of w.t. CD40 was detected only from amplified DNA samples obtained
from control w.t. B6 mice.
Flow cytometry. Spleen cells were incubated with fluorescein isothiocyanate
(FITC)- or phycoerythrin-conjugated antibodies, and direct immunofluorescence
by linear amplification (FACScan) was used to detect the expression of murine
CD4 (L3T4), CD8a (Ly2), CD3e, CD40, Thyl.2 (CD90.2), B220, CD19, CD11b,
CD11c, I-Ab, NK1.1 (NKR-PIC Ly-55), CD43 (Ly48, leukosialin), and CD5
(Ly-1) (Pharmingen, San Diego, Calif.). The appropriate FITC- or phyco-
erythrin-conjugated Ig isotype of irrelevant specificity were used to control for
each antibody.
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RESULTS AND DISCUSSION
Determination of which cellular subset(s) must express
CD154 for MAIDS pathogenesis. We challenged B6 CD154
k.o. mice with LP-BM5 virus and found that, as with anti-
CD154 MAb-treated LP-BM5-infected B6 mice from our pre-
vious studies (15, 16), such k.o. mice are resistant to developing
MAIDS. As shown in Fig. 1, LP-BM5-infected CD154 k.o.
mice did not exhibit any indications of LP-BM5-induced
MAIDS. LP-BM5-infected and uninfected B6 CD154 k.o. mice
were essentially the same with respect to spleen weights, ter-
minal IgG2a values, and spleen cell mitogenic responses to
LPS and ConA. Positive control LPBM5-infected B6 mice, in
this same experiment and consistent with our previous reports
(15, 16), compared to uninfected B6 (or CD154 k.o.) mice, had
approximately three- to fivefold-larger spleens, severalfold-in-
creased IgG2a values, completely or partially inhibited LPS
mitogen responses, and totally inhibited ConA responses.
Thus, taken together with our anti-CD154 MAb blocking stud-
FIG. 1. B6 CD154 k.o. mice do not develop MAIDS after LP-BM5 infection. B6 w.t. or CD154 k.o. mice infected with LP-BM5 virus were
sacrificed 8 weeks later. LP-BM5-infected w.t. B6, but not CD154 k.o., mice exhibited all of the positive readouts denoting LP-BM5-induced
MAIDS which were statistically different from those responses seen for uninfected mice; splenomegaly, hyper-IgG2a, and diminished or
nonexistent spleen cell response to LPS or ConA stimulation. Each bar represents a value for an individual mouse. P values were derived by the
Student t test and are represented as follows: p, P , 0.05; pp, P , 0.01; ppp, P , 0.001; NS (nonsignificant), P . 0.05. This experiment is
representative of three other experiments.
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ies, these results confirmed that functional CD154 expression
was required for LP-BM5-induced MAIDS pathogenesis.
To determine which cellular subset(s) that expresses CD154
is required for induction of MAIDS, various in vivo reconsti-
tution experiments were undertaken. The first approach in-
volved reconstituting B6 CD154 k.o. mice with purified CD41
T cells (see Materials and Methods) from w.t. B6 donors, since
CD154 expression has been found most prominently on the
CD41 T subpopulation. In three different experiments, ap-
proximately 70% of the CD41 T-cell-reconstituted CD154 k.o.
mice developed some clear signs of MAIDS after LP-BM5
challenge (data not shown).
Because the results from this experimental approach were
only suggestive that CD41 T cells were the basis for the CD154
requirement in MAIDS pathogenesis, we alternatively recon-
stituted T-cell-deficient B6 nude mice (41), in which there was
no possibility of dilution of w.t. donor, with resident k.o. re-
cipient, CD41 T cells. Nude mice, in particular B6 nude mice,
have previously been shown to be resistant to MAIDS induc-
tion (37, 47). CD41 T cells positively selected from B6 w.t. or
CD154 k.o. spleen cell suspensions were transferred 2 days
before inoculation with LP-BM5 virus. In four different exper-
iments, only the CD1541 CD41 T-cell-reconstituted, LP-BM5-
infected nude mice exhibited MAIDS, and this was consistent
across all disease readouts examined. This result was in sharp
contrast to that for the LP-BM5-infected mice which had re-
ceived CD1542 CD41 T cells. For example, as shown by the
representative experiment in Fig. 2, comparision of the mean
responses for the uninfected and infected CD1541 CD41 T-
cell-reconstituted nude mice showed that LP-BM5 infection
led to spleen weights that were approximately 7-fold higher
and serum IgG2a levels around 5,000-fold higher, and the LPS
mitogenic response was almost completely inhibited. These
MAIDS-related changes in the LP-BM5-infected, CD1541
CD41 T-cell-reconstituted mice were also significantly differ-
ent from results for both the infected nude mice that were not
reconstituted and those that received CD1542 CD41 T cells
prior to infection (Fig. 2). In addition, the ConA-dependent
mitogenic response, another index of LP-BM5-induced immu-
nodeficiency, also demonstrated the critical expression of
CD154 by the CD41 T-cell population for MAIDS pathogen-
esis. Thus, after infection, the ConA response for the CD1541
CD41 T-cell-reconstituted nude mice was statistically signifi-
cantly lower (P 5 0.0146) than the response for the CD1542
CD41 T-cell-reconstituted mice (data not shown). Of note, we
have reported in Fig. 2 and throughout the subsequent exper-
iments all readout responses that we have routinely used to
define MAIDS pathology (Fig. 1) except those that directly
measure the responsiveness of the specifically transferred cell
subset. These responses, although showing the same trend as
the other disease parameters, were somewhat more variable,
possibly because of slightly different effective cellular reconsti-
tutions on a mouse-to-mouse basis.
In contrast to CD1541 CD41 T-cell-reconstituted nude
mice, in uninfected and infected CD1542 CD41 T-cell-recon-
stituted mice, the mean spleen sizes and LPS responses (Fig. 2)
and ConA responses (data not shown) were essentially the
same, indicating that MAIDS was not induced. The 10-fold
elevation of the serum IgG2a level detected for the infected
mice was minimal compared to the 5,000-fold elevation seen in
the CD1541 CD41 T-cell-reconstituted and LP-BM5-infected
nude mice, and approximately 10-fold increases in IgG2a levels
were also found for the nonreconstituted, infected nude mice.
This pattern of slight IgG2a elevation, compared to the level
for the CD1541 CD41 T-cell transfer and infected group, was
also observed in the three repeat experiments conducted and
may represent the reported LP-BM5 virus-dependent but
MAIDS-independent increases in multiple Ig isotypes that
have been observed by two other laboratories in different k.o.
mouse models (35, 54; see below). Similarly, there was a slight
(statistically nonsignificant) increase in spleen weight for in-
FIG. 2. LP-BM5-infected B6 nude mice, which are normally
MAIDS resistant, become MAIDS susceptible after reconstitution
with CD1541 CD41 T cells but not CD1542 CD41 T cells. B6 nude
mice were intravenously reconstituted with 2 3 107 purified B6 w.t.
CD1541 or CD1542 CD41 T cells and 2 days later infected with
LP-BM5 virus. At 8 weeks after LP-BM5 infection, only the CD1541
CD41 T-cell-reconstituted mice had developed all of three positive
disease readouts indicating MAIDS susceptibility (splenomegaly, hy-
per-IgG2a, and diminished spleen cell response to LPS), which were
all statistically different from those obtained for control, reconstituted,
uninfected mice and CD1542 CD41 T-cell-reconstituted, LP-BM5-
infected nude mice. Each bar represents a mean value 6 standard
deviation. P values were derived as detailed in the legend to Fig. 1.
There were three mice for the reconstituted, uninfected group and
four mice for the reconstituted, LP-BM5-infected group. This experi-
ment is representative of three other experiments.
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fected CD1542 CD41 T-cell-reconstituted nude mice, but a
similar (and somewhat greater) increase was observed for non-
transferred infected nude mice. FITC anti-CD4 labeling of
spleen cells obtained on the day of sacrifice from CD1541 and
CD 1542 donor CD41 T-cell-reconstituted nude mice, fol-
lowed by flow cytometric analysis (see Materials and Methods),
ruled out the possibility that the MAIDS-insusceptible
CD1542 CD41 T-cell-transferred mice were not successfully
reconstituted with CD41 T cells (data not shown). From these
data, we can conclude that CD41 T cells are required and must
express CD154 for LP-BM5-induced MAIDS pathogenesis.
To test the possibility that cell subsets other than CD41 T
cells might also provide the CD154 expression requisite for
MAIDS pathogenesis, we examined CD81 T cells, a portion of
which have been reported to express CD154 in response to
antigenic stimulation (9, 19). We reconstituted B6 nude mice
with w.t. CD81 T cells (see Materials and Methods). In two
experiments, no CD81 T-cell-reconstituted, LP-BM5-infected
nude mice presented with any positive readouts indicating LP-
BM5-induced MAIDS. As shown by the representative exper-
iment in Fig. 3, LP-BM5-infected, w.t. CD81 T-cell-reconsti-
tuted nude mice exhibited mean responses for spleen size,
serum IgG2a levels, and LPS stimulation that were not signif-
icantly different from the mean responses for control, unin-
fected, CD81 T-cell-reconstituted nude mice. Spleen cells
from the CD81 T-cell-reconstituted, LP-BM5-infected nude
mice were also able to mount an allo-CTL response (see Ma-
terials and Methods) that was not significantly different from
that for uninfected CD81 T-cell-transferred nudes (P 5 0.1237
[data not shown]). Compared to the LP-BM5-infected, w.t.
CD81 T-cell-reconstituted mice represented in Fig. 3, LP-
BM5-infected, CD1541 CD41 but not CD1542 CD41 T-cell-
reconstituted nude mice, which were also included in the ex-
periment, exhibited the clear signs of MAIDS as shown in Fig.
2 (data not shown). Indeed, the responses of the CD1542
CD41 and w.t. CD1541 CD81 T-cell-reconstituted and LP-
BM5-infected mice were similar. These data strongly suggest
that w.t. CD81 T cells are not capable of providing the CD154
expression required for LP-BM5-induced MAIDS pathogene-
sis.
Thus, CD41 T cells appear to be uniquely able to provide
the CD154 expression required for induction and progression
of MAIDS. This finding is consistent with a variety of studies
indicating defects in priming and/or expansion of CD41 T cells
in CD154 k.o. mice (17, 30, 33, 49, 52). Whether this require-
ment for CD154 in these previous studies and the present
study reflects a signaling defect normally mediated by CD154
to directly activate the CD41 T cell per se, as was originally
suggested in some early studies (17, 52), or a failure to activate
and mature CD401 B cells or professional antigen-presenting
cells to function and/or traffic appropriately (33) was unclear.
However, because the bulk of the literature now generally
favors an effect mediated by the lack of signaling through
CD40 (30), we focused next on identification of the possible
CD401 cell subsets required for MAIDS.
Determination of which cellular subset(s) must express
CD40 for MAIDS pathogenesis. We and others (54) have
found that, like CD154 k.o. mice, B6 CD40 k.o. mice are
resistant to LP-BM5-induced MAIDS, although the degree of
resistance is somewhat less dramatic than for CD154 k.o. mice.
These findings provided confirmation of our conclusion that
CD154-CD40 interactions are required, based on the results
from our studies showing an interference with MAIDS initia-
tion and progression by treatment with blocking anti-CD154
MAb (15, 16). CD40, originally identified as a B-cell molecule,
has also been reported to be expressed prominently by DC and
macrophages (48), as well as by other cell types. To determine
which cellular subsets must express CD40 for LP-BM5-induced
MAIDS pathogenesis, we performed parallel reconstitutions
of normally MAIDS-resistant B6 CD40 k.o. mice with three
different B6 background-derived sources of CD401 cells: (i)
highly purified CD401 B cells; (ii) purified CD401 DC; and
(iii) B6 SCID spleen cells, representing a combined population
of CD401 DC and macrophages. We found that only CD401
B-cell-reconstituted CD40 k.o. mice became MAIDS suscep-
FIG. 3. CD1541 CD81 T-cell-reconstituted B6 nude mice remain
MAIDS insusceptible after LP-BM5 infection. B6 nude mice were
reconstituted with 107 purified CD1541 CD81 T cells and 2 days later
were infected with LP-BM5 virus. At 8 weeks postinfection, all recip-
ient mice were sacrificed and the indicated disease parameters indic-
ative of MAIDS were determined. Each bar represents a mean value 6
standard deviation. This is representative of one other experiment. P
values shown were derived by the Student t test (NS [not significant],
P . 0.05).
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tible after LP-BM5 infection. Thus, compared to the minimal
to moderate effects seen for LP-BM5 infection of nonrecon-
stituted CD40 k.o. mice, CD401 B-cell-reconstituted, LP-
BM5-infected CD40 k.o. mice exhibited MAIDS by statistically
significant differences for mean spleen size, serum IgG2a lev-
els, allo-CTL responsiveness (Fig. 4), and LPS responsiveness
(P 5 0.0272, data not shown). Of note, the observed serum
hyper-Ig levels were 2 fold higher than that seen in LP-BM5-
infected B6 control mice (data not shown). These responses
for CD401 B-cell-reconstituted, LP-BM5-infected mice were
also statistically different from those obtained for CD401 DC-
reconstituted, LP-BM5-infected CD40 k.o. mice (see also be-
low). A similar pattern of results was found in another exper-
iment in which CD40 k.o. mice were again reconstituted with
7 3 107 CD401 B cells, representing approximately 1.1 splenic
equivalents, before they were infected with LP-BM5. In two
earlier experiments in which CD40 k.o. mice were reconsti-
tuted with either 2 3 107 or 5 3 107 CD401 B cells, LPBM5-
induced MAIDS also occurred, but there was more mouse-to-
mouse variability.
To address the possible ability of alternative CD40-express-
ing cellular subsets to provide the CD40 expression required
for MAIDS pathogenesis in the absence of CD40-expressing B
cells, we reconstituted CD40 k.o. mice in parallel with 5 3 106
(. 10 splenic equivalents) purified CD401 DC. No MAIDS
induction was observed in such CD401 DC-reconstituted
CD40 k.o. mice 11 weeks after LP-BM5 infection compared to
nontransferred, LP-BM5-infected CD40 k.o. controls (Fig. 4).
In addition to the allo-CTL data, there was no evidence for
immunosuppression based on LPS responsiveness (P 5 0.1066
[data not shown]). A repeat experiment in which more (107)
DC were used for reconstitution produced the same result: all
FIG. 4. MAIDS-resistant LP-BM5-infected B6 CD40 k.o. mice become MAIDS susceptible after reconstitution with CD401 B cells but not
after reconstitution with CD401 DC. CD40 k.o. mice were intravenously reconstituted with 7 3 107 highly purified B6 CD401 B cells or 5 3 106
CD401 purified DC obtained from Flt3-treated B6 mice. Two days later they were infected with LP-BM5 virus, and at 11 weeks postinfection, the
recipients were sacrificed for the indicated disease parameters indicating MAIDS susceptibility: splenomegaly, hyper-IgG2a, and diminished
allo-CTL responses. Serum IgG2a levels for LP-BM5-infected nonreconstituted CD40 k.o. mice are higher than those for noninfected k.o. mice,
apparently in accordance with the published observation that LP-BM5 causes hyper-IgG2a due to a virus-dependent but non-MAIDS-related
isotype class switching in CD40 k.o. mice (54). Each bar represents the mean response 6 standard deviation. P values were derived as detailed
in the legend to Fig. 1. This experiment is representative of one other. A less consistent but similar trend of responses was seen in two other
experiments in which 2 3 107 and 5 3 107 purified CD401 B cells were transferred (see text). E:T, effector:target.
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LP-BM5-infected, DC-reconstituted CD40 k.o. mice had
spleen weights, IgG2a levels, and LPS and allo-CTL responses
similar to those seen in LP-BM5-infected, nonreconstituted
CD40 k.o. mice. Of note, CD401 CD11c1 donor DC were
detected in about half of the mice by flow cytometric analysis
on the day of sacrifice in the spleens of reconstituted mice
(mean delta percent positive of 1 to 2%). These results were
confirmed by the presence of the expected 900-bp band indic-
ative of w.t. CD40 following PCR amplification of DNA also
extracted at sacrifice from the reconstituted recipients (see
Materials and Methods). While it seems likely that more dra-
matic evidence controlling for the presence of the donor DC
populations would have been obtained if recipients could have
been analyzed before their sacrifice at 11 weeks after transfer
and infection, and considering that because no disease oc-
curred, there was no expansion of the transferred cells, we take
these results to be reasonable evidence of the success of the
reconstitution (see also Materials and Methods regarding the
transfers).
As an alternative approach to assessing non-B-cell sources
of CD401 cells for their possible role in MAIDS, CD40 k.o.
mice were alternatively reconstituted with 5 3 106 B6 SCID (4)
spleen cells as a source of both CD401 DC and macrophages.
Of note, SCID mice have previously been shown by Simard et
al. to be resistant to induction of MAIDS, albeit in experiments
using the alternative Du5H (Du5H/Mo-LTR) rescued chi-
meric defective virus (47). Such transferred SCID mouse
spleen cell subsets, which have been reported as competent
antigen-presenting cells (10), did not render CD40 k.o. recip-
ients MAIDS susceptible. Thus, there were no positive read-
outs indicating LP-BM5-induced MAIDS at 11 weeks after
LP-BM5 infection (Fig. 5).
In conclusion, collectively these data strongly suggest that
with respect strictly to the CD1541 and CD401 cellular re-
quirements for disease, CD41 T cells expressing CD154 and
B-cells expressing CD40 are necessary and sufficient for LP-
BM5 MuLV-induced MAIDS pathogenesis. Further, in the
absence of CD401 B cells, macrophages, and/or DC, despite
their CD40 positivity, are unable to provide the functional
CD40 expression for LP-BM5-induced MAIDS. However, we
cannot exclude a role for macrophages or DC in MAIDS
pathogenesis in a manner that does not involve their display of
CD40. Of note, flow cytometric analyses indicated that the
highly purified B-cell preparations, which allowed for LP-BM5
induction of MAIDS in reconstituted CD40 k.o. mice, were
negative not only for CD11c- or CD11b-expressing DC or
macrophages but also for CD51 CD191 double-positive B
cells. Thus, it would appear from our data that this latter B-la
subset of B cells is not essential as the cellular basis of the
CD40 requirement in MAIDS. This finding is relevant to the
ongoing debate as to the importance of B-la B cells in MAIDS
pathogenesis (20, 50). Our data clearly imply that if B-la B cells
have any role in MAIDS pathogenesis, then at least this puta-
tive function does not depend on the expression of CD40.
The results from our previous studies and herein, in which
we have defined CD1541 CD41 T cells and CD401 B cells as
the cellular subsets which must express these two paired inter-
acting molecules for LP-BM5-induced MAIDS initiation and
progression, thus provide the basis for further experimentation
in which we will explore the molecular signaling cascades em-
anating from CD40 (and possibly CD154) that appear central
to MAIDS pathogenesis. However, other receptor-ligand pairs
may also be critical to disease induction. Along these lines, De
Leval et al. recently reported that MAIDS pathogenesis in
LP-BM5-infected B6 mice could be partially blocked by in vivo
treatment with soluble CTLA4Ig (12) or more completely by
the transgenic overexpression of soluble CTLA4 (11). Whether
the critical manifestation of CD40 signaling in MAIDS is in-
deed the upregulation on B cells of CD80 and/or CD86 and a
subsequent interaction with T cells expressing CD28 and
FIG. 5. B6 CD40 k.o. mice do not develop LP-BM5-induced
MAIDS after reconstitution with a cell preparation enriched for
CD401 DC and macrophages. CD40 k.o. mice were intravenously
reconstituted with 5 3 106 spleen cells obtained form B6 SCID mouse
donors; they were infected with LP-BM5 2 days later and assessed for
the indicated MAIDS disease parameters at 11 weeks postinfection.
Each bar represents the mean 6 standard deviation. Serum IgG2a
levels for LP-BM5-infected nonreconstituted CD40 k.o. mice are
higher than those for uninfected k.o. mice, apparently in accordance
with the published observation that LP-BM5 causes hyper-IgG1 and
-IgE, (54) due to a virus-dependent but non-MAIDS-related isotype
class switching in CD40 k.o. mice. P values were derived by the Student
t test (NS [nonsignificant], P . (0.05). E:T, effector:target.
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CTLA4 will await future studies. Similarly, evidence suggesting
that the receptor ligands CD11a/CD18 (LFA-1) and CD54
(ICAM-1) are required for MAIDS development has been
presented (31). Whether these molecules aid in the interaction
of CD41 T cells with B cells prior to delivery of signals from
CD154 to CD40 or there is a role for LFA-1–ICAM-1 inter-
actions subsequent to CD40 signaling is unclear.
Our results on the requirement for interactions between
CD401 B cells and CD1541 CD41 T cells in the initiation and
progression of MAIDS are interesting in the context of other
retrovirus-induced immunodeficiencies, specifically human
AIDS. Particularly relevant to the present study, several recent
reports have defined CD154-CD40 interactions that may be
important to HIV infectivity and/or pathogenesis. In a study by
Poulin et al. (42), human B lymphocytes activated in vitro with
murine cell surface-presented CD154 in the presence of inter-
leukin-4 became infectable by HIV type 1 (HIV-1). When such
infected B cells were cocultured with an HIV-1-susceptible
CD41 T-cell line, B-T cell fusion and syncytium formation led
to direct infection of the T cells (42). In a follow-up report, it
was further found that culturing freshly isolated B lymphocytes
with soluble oligomeric CD154 plus interleukin-4 upregulated
B-cell CD4 and CXCR4 receptor expression, with subsequent
greatly increased susceptibility to infection by T-cell-tropic and
dualtropic strains of HIV but not by macrophagetropic strains.
The authors speculated that CD40 activation-dependent con-
version of B cells to HIV-1 susceptibility may make the B
lymphocyte a potential viral reservoir in AIDS patients (32).
Similarly, Gras et al. (14) have provided data suggesting that
activation through CD40 augments HIV replication in B cells.
Furthermore, Muller et al. (38) have reported that the poly-
clonal hyper-Ig characteristic of HIV-infected patients may
relate to the observed increases in the percentage of CD41 T
cells expressing CD154 and in the density of cell surface CD40
expressed by B cells.
Because evidence has been provided that in MAIDS B cells
are the primary cell type for expression of the disease-causing
defective retrovirus (21, 25), further study of the effects of
CD154-CD40 activation and downstream molecular signaling
interactions in LPBM5-infected B cells may provide additional
insights into the role of B cells in MAIDS and potentially the
pathogenesis of other retrovirus-induced immunodeficiencies,
including AIDS. Such new information, particularly if B cells
do constitute a retroviral reservoir, may be useful in improving
existing, or developing new, strategies involving the use of
antiviral drug therapies or other approaches to eliminate re-
sidual retrovirus.
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